GILD News & Events

Gilead Sciences announced the presentation of new Phase 3 ARTISTRY-1 and ARTISTRY-2 trial data at CROI 2026 showing a treatment switch to an investigational, single-tablet combination regimen of bictegravir 75 mg/lenacapavir 50 mg was effective in people living with HIV with virological suppression, including those switching from complex multi-tablet regimens or a global guideline-recommended single-tablet regimen. The novel combination of BIC/LEN was generally well tolerated, with no significant or new safety concerns identified, the company said. "The ARTISTRY trials represent the latest example of Gilead's commitment to advancing HIV treatment through continuous scientific innovation," said Jared Baeten, M.D., Ph.D., Senior Vice President, Clinical Development, Virology Therapeutic Area Head, Gilead Sciences. "This once-daily single-tablet regimen combines the durability of bictegravir with lenacapavir, a first-in-class capsid inhibitor. The novel treatment combination is designed to sustain virologic suppression for those seeking new options. We look forward to working with regulatory authorities to potentially bring this combination forward to people with HIV."

Stifel downgraded Arcellx (ACLX) to Hold from Buy with a price target of $115, down from $127, following the announcement that Gilead (GILD) is acquiring the company for $115 per share. The firm continues to believe that the likely 2026-end approval of anito-cel in 4L+ patients will result in one of the most successful oncology launches, with longer-term label expansion into second-line patients serving as the primary lever underlying its $7B peak global sales estimate, the analyst tells investors in a research note.